Significant	JJ
involvement	NN
of	IN
CCL2	NN
(	(
MCP-1	NN
)	)
in	IN
inflammatory	JJ
disorders	NNS
of	IN
the	DT
lung	NN
.	.

Mounting	VBG
evidence	NN
suggests	VBZ
that	IN
CCL2	NN
(	(
MCP-1	NN
)	)
and	CC
its	PRP$
hematopoietic	JJ
cell	NN
receptor	NN
CC-chemokine-receptor-2	NN
(	(
CCR2	NN
)	)
are	VBP
involved	VBN
in	IN
inflammatory	JJ
disorders	NNS
of	IN
the	DT
lung	NN
.	.

In	IN
animal	NN
models	NNS
of	IN
allergic	JJ
asthma	NN
,	,
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
,	,
and	CC
bronchiolitis	NN
obliterans	NNS
syndrome	NN
(	(
BOS	NN
)	)
,	,
CCL2	NN
expression	NN
and	CC
protein	NN
production	NN
are	VBP
increased	VBN
and	CC
the	DT
disease	NN
process	NN
is	VBZ
attenuated	VBN
by	IN
CCL2	NN
immunoneutralization	NN
.	.

Mechanisms	NNS
by	IN
which	WDT
CCL2	NN
may	MD
be	VB
acting	VBG
include	VBP
recruitment	NN
of	IN
regulatory	JJ
and	CC
effector	NN
leukocytes	NNS
;	:
stimulation	NN
of	IN
histamine	NN
or	CC
leukotriene	NN
release	NN
from	IN
mast	NN
cells	NNS
or	CC
basophils	NNS
;	:
induction	NN
of	IN
fibroblast	NN
production	NN
of	IN
transforming-growth-factor-beta	NN
(	(
TGF-beta	NN
)	)
and	CC
procollagen	NN
;	:
and	CC
enhancement	NN
of	IN
Th2	NN
polarization	NN
.	.

Recently	RB
,	,
polymorphism	NN
for	IN
CCL2	NN
has	VBZ
been	VBN
described	VBN
with	IN
increased	VBN
cytokine-induced	JJ
release	NN
of	IN
CCL2	NN
by	IN
monocytes	NNS
and	CC
increased	VBD
risk	NN
of	IN
allergic	JJ
asthma	NN
.	.

These	DT
studies	NNS
identify	VBP
potentially	RB
important	JJ
roles	NNS
for	IN
CCL2	NN
in	IN
these	DT
lung	NN
inflammatory	JJ
disorders	NNS
.	.

While	IN
CCL2	NN
inhibition	NN
in	IN
patients	NNS
with	IN
acute	JJ
respiratory	JJ
distress	NN
syndrome	NN
(	(
ARDS	NN
)	)
may	MD
be	VB
hazardous	JJ
by	IN
interfering	VBG
with	IN
defense	NN
against	IN
bacteremia	NN
,	,
future	JJ
studies	NNS
are	VBP
needed	VBN
to	TO
determine	VB
if	IN
CCL2/CCR2	NN
antagonism	NN
will	MD
offer	VB
breakthrough	NN
therapy	NN
for	IN
patients	NNS
with	IN
allergic	JJ
asthma	NN
,	,
IPF	NN
,	,
or	CC
BOS	NNP
,	,
and	CC
to	TO
confirm	VB
the	DT
hypothesis	NN
that	IN
CCL2	NN
polymorphism	NN
places	NNS
patients	NNS
at	IN
greater	JJR
risk	NN
for	IN
these	DT
disorders	NNS
.	.

